News articles about ADMA Biologics (NASDAQ:ADMA) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ADMA Biologics earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.0449178147238 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
ADMA Biologics stock traded up $0.08 during midday trading on Friday, hitting $5.19. 115,059 shares of the stock were exchanged, compared to its average volume of 115,546. ADMA Biologics has a 52-week low of $2.01 and a 52-week high of $5.38. The stock has a market cap of $128.19, a PE ratio of -2.72 and a beta of 2.10. The company has a debt-to-equity ratio of 2.26, a quick ratio of 1.35 and a current ratio of 2.36.
ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.27. The business had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $6.68 million. ADMA Biologics had a negative net margin of 58.67% and a negative return on equity of 133.15%. analysts predict that ADMA Biologics will post -1.38 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was published by BBNS and is the property of of BBNS. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://baseballnewssource.com/2018/04/06/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-adma-biologics-adma-share-price/2037281.html.
About ADMA Biologics
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.